These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 20182025)

  • 81. Comparability of [
    Rodriguez-Vieitez E; Leuzy A; Chiotis K; Saint-Aubert L; Wall A; Nordberg A
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review.
    Rice L; Bisdas S
    Eur J Radiol; 2017 Sep; 94():16-24. PubMed ID: 28941755
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes.
    Lee YH; Jeon S; Yoo HS; Chung SJ; Jung JH; Baik K; Sohn YH; Lee PH; Yun M; Evans AC; Ye BS
    J Alzheimers Dis; 2021; 79(4):1471-1487. PubMed ID: 33459638
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
    Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.
    Neale N; Padilla C; Fonseca LM; Holland T; Zaman S
    Neuroimage Clin; 2018; 17():263-271. PubMed ID: 29159043
    [TBL] [Abstract][Full Text] [Related]  

  • 86. PET Imaging in Preclinical Anti-Aβ Drug Development.
    Syvänen S; Meier SR; Roshanbin S; Xiong M; Faresjö R; Gustavsson T; Bonvicini G; Schlein E; Aguilar X; Julku U; Eriksson J; Sehlin D
    Pharm Res; 2022 Jul; 39(7):1481-1496. PubMed ID: 35501533
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Advances in Brain Amyloid Imaging.
    Krishnadas N; Villemagne VL; Doré V; Rowe CC
    Semin Nucl Med; 2021 May; 51(3):241-252. PubMed ID: 33482999
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cerebral amyloid PET imaging in Alzheimer's disease.
    Jack CR; Barrio JR; Kepe V
    Acta Neuropathol; 2013 Nov; 126(5):643-57. PubMed ID: 24100688
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Usefulness of Brain Positron Emission Tomography with Different Tracers in the Evaluation of Patients with Idiopathic Normal Pressure Hydrocephalous.
    Mattoli MV; Treglia G; Calcagni ML; Mangiola A; Anile C; Trevisi G
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906629
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies.
    Mosconi L
    Clin Transl Imaging; 2013 Aug; 1(4):. PubMed ID: 24409422
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Lack of association between cortical amyloid deposition and glucose metabolism in early stage Alzheimer´s disease patients.
    Ehrlich D; Dunzinger A; Malsiner-Walli G; Grün B; Topakian R; Hodolic M; Kainz E; Pichler R
    Radiol Oncol; 2021 Dec; 56(1):23-31. PubMed ID: 34957735
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.
    Shokouhi S; Claassen D; Riddle W
    J Alzheimers Dis Parkinsonism; 2014 Apr; 4(2):. PubMed ID: 25343059
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Development of
    Staudt M; Shalgunov V; Nedergaard M; Herth MM
    J Labelled Comp Radiopharm; 2023 Oct; 66(12):393-399. PubMed ID: 37653688
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Brain imaging in Alzheimer disease.
    Johnson KA; Fox NC; Sperling RA; Klunk WE
    Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a006213. PubMed ID: 22474610
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Brain injury biomarkers are not dependent on β-amyloid in normal elderly.
    Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Ann Neurol; 2013 Apr; 73(4):472-80. PubMed ID: 23424032
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Validity and value of metabolic connectivity in mouse models of β-amyloid and tauopathy.
    Ruch F; Gnörich J; Wind K; Köhler M; Zatcepin A; Wiedemann T; Gildehaus FJ; Lindner S; Boening G; von Ungern-Sternberg B; Beyer L; Herms J; Bartenstein P; Brendel M; Eckenweber F
    Neuroimage; 2024 Feb; 286():120513. PubMed ID: 38191101
    [TBL] [Abstract][Full Text] [Related]  

  • 97. PET molecular imaging for pathophysiological visualization in Alzheimer's disease.
    Wang J; Jin C; Zhou J; Zhou R; Tian M; Lee HJ; Zhang H
    Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):765-783. PubMed ID: 36372804
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The concept of FDG-PET endophenotype in Alzheimer's disease.
    During EH; Osorio RS; Elahi FM; Mosconi L; de Leon MJ
    Neurol Sci; 2011 Aug; 32(4):559-69. PubMed ID: 21630036
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Brain metabolic network covariance and aging in a mouse model of Alzheimer's disease.
    Chumin EJ; Burton CP; Silvola R; Miner EW; Persohn SC; Veronese M; Territo PR
    Alzheimers Dement; 2024 Mar; 20(3):1538-1549. PubMed ID: 38032015
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Astrocyte Signature in Alzheimer's Disease Continuum through a Multi-PET Tracer Imaging Perspective.
    Fontana IC; Scarpa M; Malarte ML; Rocha FM; Ausellé-Bosch S; Bluma M; Bucci M; Chiotis K; Kumar A; Nordberg A
    Cells; 2023 May; 12(11):. PubMed ID: 37296589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.